PTX3 and Huntington disease: More recently, Suliman et al. [58] analyzed plasma PTX-3 concentrations in relation to comorbidities (Davies score), protein-energy wasting (PEW), and inflammation markers in 200 prevalent HD patients, aged  64 ± 14  years, who had been on HD treatment for a median period of 36 months.